Global Angiotensin Converting Enzyme (ACE) Inhibitors Market – Industry Trends and Forecast to 2030

Análise e dimensão do mercado de inibidores da enzima conversora da angiotensina (IECA)

O rápido aumento da incidência de doenças cardiovasculares está entre os fatores essenciais que intensificam o crescimento e a procura do mercado de inibidores da enzima conversora da angiotensina (IECA). Além disso, o aumento da prevalência da hipertensão está também a contribuir para o aumento do mercado global. O risco crescente de desenvolver hipertensão arterial e distúrbios cardiovasculares devido à mudança do estilo de vida é também o fator-chave para o florescimento do mercado dos inibidores da enzima conversora da angiotensina (IECA).

A Data Bridge Market Research analisa que o mercado dos inibidores da enzima conversora da angiotensina (IECA), que foi de 3.456,27 milhões de dólares em 2022, subiria para 9.520,26 milhões de dólares até 2030 e deverá passar por um CAGR de 4 ,9% durante o período de previsão. Isto indica que o valor de mercado. Os “agentes contendo dicarboxilato” dominam o segmento de tipo de produto do Mercado de Inibidores da Enzima de Conversão da Angiotensina (ECA) devido à crescente procura destes tipos de agentes contendo. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado de inibidores da enzima conversora da angiotensina (ACE)

Definição de mercado

Os inibidores da ECA são medicamentos utilizados para tratar e controlar a hipertensão, que é um fator de risco significativo para a doença coronária, insuficiência cardíaca, acidente vascular cerebral e uma série de outras condições cardiovasculares. A maioria dos casos é primária e não atribuível a nenhuma etiologia específica.

Dinâmica do mercado dos inibidores da enzima conversora da angiotensina (IECA)

Motoristas

• Aumento da incidência de doenças cardiovasculares

A crescente prevalência de doenças cardiovasculares está entre os fatores essenciais que intensificam o crescimento e a procura do mercado de inibidores da enzima conversora da angiotensina (IECA). Isto, por sua vez, abriu caminho para o crescimento do mercado.

• Proficiências em investigação e desenvolvimento

O aumento das despesas com competências em investigação e desenvolvimento, especialmente nas economias desenvolvidas e em desenvolvimento, relativas aos instrumentos e dispositivos médicos, criará ainda mais oportunidades lucrativas de crescimento do mercado. As proficiências em investigação e desenvolvimento conduzidas para desenvolver os instrumentos médicos estão também a reforçar a taxa de crescimento do mercado.

Oportunidade

• Investimento crescente em instalações de saúde

O crescente foco na melhoria das condições das instalações de saúde e na melhoria das infraestruturas gerais de saúde é outro fator importante que promove o crescimento do mercado. O número crescente de parcerias e colaborações estratégicas entre os intervenientes públicos e privados relativos ao financiamento e aplicação de tecnologias novas e melhoradas está a criar ainda mais oportunidades de mercado lucrativas.  

Restrições/Desafios

• Elevado custo associado às proficiências em investigação e desenvolvimento

High cost associated with the research and development proficiencies, limited infrastructural facilities, products and dearth of awareness in the backward economies are expected to obstruct market growth. Also, lack of favorable reimbursement scenario and technology penetration in the developing economies, and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2023-2030.

This Angiotensin Converting Enzyme (ACE) inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Angiotensin Converting Enzyme (ACE) Inhibitors Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In May 2021, Novartis announced that it had received FDA approval for its new ACE inhibitor drug, Entresto, for the treatment of heart failure. This drug has been shown to reduce the risk of hospitalization and death in patients with heart failure.

• In November 2020, Pfizer and BioNTech announced the results of their clinical trial of the COVID-19 vaccine, which showed that it was 95% effective. Pfizer is a leading producer of ACE inhibitors, and the success of the COVID-19 vaccine has been a major development for the company.

Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Scope

The Angiotensin Converting Enzyme (ACE) inhibitors market is segmented on the basis of product type, drug, dosage form, application and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Dicarboxylate-Containing Agents
• Phosphonate-Containing Agents
• Sulfhydryl-Containing Agents

Drug

• Lisinopril
• Ramipril
• Enalapril
• Benazepril
• Fosinopril
• Captopril
• Moexipril 
• Others

Dosage Form

• Oral Tablet
• Oral Solution

Application

• Heart Failure
• Hypertension
• Diabetes
• Heart Attack
• Chronic Kidney Disease
• Others

Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• E-Commerce Websites
• Online Drug Stores

Angiotensin Converting Enzyme (ACE) Inhibitors Market Regional Analysis/Insights

The Angiotensin Converting Enzyme (ACE) inhibitors market is analysed and market size insights and trends are provided by country, product type, drug, dosage form, application and distribution channel as referenced above.

The countries covered in the Angiotensin Converting Enzyme (ACE) inhibitors market  report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the Angiotensin Converting Enzyme (ACE) inhibitors market because of the strong base of healthcare facilities, strong presence of major players in the market, increases cases of cardiovascular diseases among the population and rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in healthcare facilities, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The Angiotensin Converting Enzyme (ACE) inhibitors market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Angiotensin Converting Enzyme (ACE) Inhibitors Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Angiotensin Converting Enzyme (ACE) Inhibitors Market. The data is available for historic period 2010-2020.

Competitive Landscape and Angiotensin Converting Enzyme (ACE) Inhibitors Market Share Analysis

The Angiotensin Converting Enzyme (ACE) inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Angiotensin Converting Enzyme (ACE) Inhibitors market.

Some of the major players operating in the Angiotensin Converting Enzyme (ACE) inhibitors market are:

• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Merck & Co. (U.S.)
• AstraZeneca (UK)
• Sanofi (France)
• Boehringer Ingelheim (Germany)
• GlaxoSmithKline (U.K.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Lupin Limited (India)
• Cipla (India)
• Torrent Pharmaceuticals Ltd. (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Dr. Reddy's Laboratories Ltd. (India)
• Cadila Healthcare Limited (India)
• Macleods Pharmaceuticals Limited (India)
• Zydus Cadila (India)
• Mylan (US)
• Sandoz (Germany)
• Accord Healthcare (U.K.)
• Apotex (Canada)

SKU-58786